AbbVie Nov 22, 2026 Copy link AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference NORTH CHICAGO, Ill., Nov. 20, 2026 Business
AbbVie Nov 3, 2026 Copy link Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026 IRVINE, Calif., Nov. 3, 2026 Business
AbbVie Oct 30, 2026 Copy link AbbVie Reports Third-Quarter 2026 Financial Results NORTH CHICAGO, Ill., Oct. 30, 2026 Business
AbbVie Oct 28, 2026 Copy link The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18 IRVINE, Calif., Oct. 28, 2026 Business
AbbVie Oct 27, 2026 Copy link Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc. IRVINE, Calif., Oct. 26, 2026 Business
AbbVie Oct 27, 2026 Copy link Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA) IRVINE, Calif., Oct. 27, 2026 Business
AbbVie Oct 27, 2026 Copy link AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma NORTH CHICAGO, Ill., Oct. 27, 2026 Business
AbbVie Oct 23, 2026 Copy link U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie’s SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn’s Disease NORTH CHICAGO, Ill., Oct. 23, 2026 Business
AbbVie Oct 22, 2026 Copy link AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa NORTH CHICAGO, Ill., Oct. 22, 2026 Business
AbbVie Oct 21, 2026 Copy link AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community NORTH CHICAGO, Ill., Oct. 20, 2026 Business
AbbVie Oct 21, 2026 Copy link Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence IRVINE, Calif., Oct. 21, 2026 Business
AbbVie Oct 20, 2026 Copy link SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 NORTH CHICAGO, Ill., Oct. 17, 2026 Business